Argonaute 2: A novel rising star in cancer research

Journal of Cancer

Volumn 6, Issue 9, 2015, Pages 877-882

  Ye, ZhenLong ^a   Jin, HuaJun ^a   Qian, QiJun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Argonaute 2; Carcinomas; MicroRNAs

Indexed keywords

ARGONAUTE 2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GUIDE RNA; PIWI PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE;

ANGIOGENESIS; CANCER RESEARCH; CANCER STAGING; CARCINOMA; ENZYME ACTIVE SITE; GENE EXPRESSION; GENE SILENCING; HETEROCHROMATIN; HUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; RNA TRANSLATION;

EID: 84947738607     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11735     Document Type: Review

References (61)

1. Hock J, Meister G: The Argonaute protein family. Genome biology 2008, 9(2):210.
2. Meister G: Argonaute proteins: functional insights and emerging roles. Nature reviews Genetics 2013, 14(7):447-459.
3. Schirle NT, MacRae IJ: The crystal structure of human Argonaute2. Science 2012, 336(6084):1037-1040.
4. Morita S, Horii T, Kimura M, Goto Y, Ochiya T, Hatada I: One Argonaute family member, Eif2c2 (Ago2), is essential for development and appears not to be involved in DNA methylation. Genomics 2007, 89(6):687-696.
5. Shekar PC, Naim A, Sarathi DP, Kumar S: Argonaute-2-null embryonic stem cells are retarded in self-renewal and differentiation. Journal of biosciences 2011, 36(4):649-657.
6. Kuhn CD, Joshua-Tor L: Eukaryotic Argonautes come into focus. Trends in biochemical sciences 2013, 38(5):263-271.
7. Kwak PB, Tomari Y: The N domain of Argonaute drives duplex unwinding during RISC assembly. Nature structural & molecular biology 2012, 19(2):145-151.
8. Wang Y, Juranek S, Li H, Sheng G, Wardle GS, Tuschl T, Patel DJ: Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature 2009, 461(7265):754-761.
9. Ma JB, Ye K, Patel DJ: Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 2004, 429(6989):318-322.
10. Song JJ, Liu J, Tolia NH, Schneiderman J, Smith SK, Martienssen RA, Hannon GJ, Joshua-Tor L: The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nature structural biology 2003, 10(12):1026-1032.
11. Gu S, Jin L, Huang Y, Zhang F, Kay MA: Slicing-independent RISC activation requires the argonaute PAZ domain. Current biology: CB 2012, 22(16):1536-1542.
12. Boland A, Huntzinger E, Schmidt S, Izaurralde E, Weichenrieder O: Crystal structure of the MID-PIWI lobe of a eukaryotic Argonaute protein. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(26):10466-10471.
13. Boland A, Tritschler F, Heimstadt S, Izaurralde E, Weichenrieder O: Crystal structure and ligand binding of the MID domain of a eukaryotic Argonaute protein. EMBO reports 2010, 11(7):522-527.
14. Parker JS, Roe SM, Barford D: Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature 2005, 434(7033):663-666.
15. Girard A, Sachidanandam R, Hannon GJ, Carmell MA: A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 2006, 442(7099):199-202.
16. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T: Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Molecular cell 2004, 15(2):185-197.
17. Choe J, Cho H, Lee HC, Kim YK: microRNA/Argonaute 2 regulates nonsense-mediated messenger RNA decay. EMBO reports 2010, 11(5):380-386.
18. Borner K, Niopek D, Cotugno G, Kaldenbach M, Pankert T, Willemsen J, Zhang X, Schurmann N, Mockenhaupt S, Serva A et al: Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic acids research 2013, 41(21):e199.
19. Kiriakidou M, Tan GS, Lamprinaki S, De Planell-Saguer M, Nelson PT, Mourelatos Z: An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell 2007, 129(6):1141-1151.
20. Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RI, Liebhaber SA, Pasquinelli AE, Shiekhattar R: MicroRNA silencing through RISC recruitment of eIF6. Nature 2007, 447(7146):823-828.
21. Chen CY, Zheng D, Xia Z, Shyu AB: Ago-TNRC6 triggers microRNA-mediated decay by promoting two deadenylation steps. Nature structural & molecular biology 2009, 16(11):1160-1166.
22. Friend K, Campbell ZT, Cooke A, Kroll-Conner P, Wickens MP, Kimble J: A conserved PUF-Ago-eEF1A complex attenuates translation elongation. Nature structural & molecular biology 2012, 19(2):176-183.
23. Moshkovich N, Nisha P, Boyle PJ, Thompson BA, Dale RK, Lei EP: RNAi-independent role for Argonaute2 in CTCF/CP190 chromatin insulator function. Genes & development 2011, 25(16):1686-1701.
24. Ameyar-Zazoua M, Rachez C, Souidi M, Robin P, Fritsch L, Young R, Morozova N, Fenouil R, Descostes N, Andrau JC et al: Argonaute proteins couple chromatin silencing to alternative splicing. Nature structural & molecular biology 2012, 19(10):998-1004.
25. Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ: A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 2010, 465(7298):584-589.
26. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, Hannon GJ, Lawson ND et al: A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 2010, 328(5986):1694-1698.
27. Winter J, Diederichs S: Argonaute proteins regulate microRNA stability: Increased microRNA abundance by Argonaute proteins is due to microRNA stabilization. RNA biology 2011, 8(6):1149-1157.
28. Li L, Yu C, Gao H, Li Y: Argonaute proteins: potential biomarkers for human colon cancer. BMC cancer 2010, 10:38.
29. Chang SS, Smith I, Glazer C, Hennessey P, Califano JA: EIF2C is overexpressed and amplified in head and neck squamous cell carcinoma. ORL; journal for oto-rhino-laryngology and its related specialties 2010, 72(6):337-343.
30. Yang FQ, Huang JH, Liu M, Yang FP, Li W, Wang GC, Che JP, Zheng JH: Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder. International journal of clinical and experimental pathology 2014, 7(1):340-347.
31. Vaksman O, Hetland TE, Trope CG, Reich R, Davidson B: Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Human pathology 2012, 43(11):2062-2069.
32. Zhang J, Fan XS, Wang CX, Liu B, Li Q, Zhou XJ: Up-regulation of Ago2 expression in gastric carcinoma. Med Oncol 2013, 30(3):628.
33. Papachristou DJ, Korpetinou A, Giannopoulou E, Antonacopoulou AG, Papadaki H, Grivas P, Scopa CD, Kalofonos HP: Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas. Virchows Archiv: an international journal of pathology 2011, 459(4):431-440.
34. Feng B, Hu P, Lu SJ, Chen JB, Ge RL: Increased argonaute 2 expression in gliomas and its association with tumor progression and poor prognosis. Asian Pacific journal of cancer prevention: APJCP 2014, 15(9):4079-4083.
35. Zhang J, Jin H, Liu H, Lv S, Wang B, Wang R, Ding M, Yang Y, Li L, Fu S et al: MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis 2014, 3:e97.
36. Cheng N, Li Y, Han ZG: Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma. Hepatology 2013, 57(5):1906-1918.
37. Papachristou DJ, Sklirou E, Corradi D, Grassani C, Kontogeorgakos V, Rao UN: Immunohistochemical analysis of the endoribonucleases Drosha, Dicer and Ago2 in smooth muscle tumours of soft tissues. Histopathology 2012, 60(6B):E28-36.
38. Yoo NJ, Hur SY, Kim MS, Lee JY, Lee SH: Immunohistochemical analysis of RNA-induced silencing complex-related proteins AGO2 and TNRC6A in prostate and esophageal cancers. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 2010, 118(4):271-276.
39. Wu S, Yu W, Qu X, Wang R, Xu J, Zhang Q, Li J, Chen L: Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation. Journal of hematology & oncology 2014, 7(1):40.
40. Voller D, Reinders J, Meister G, Bosserhoff AK: Strong reduction of AGO2 expression in melanoma and cellular consequences. British journal of cancer 2013, 109(12):3116-3124.
41. Zhang X, Graves P, Zeng Y: Overexpression of human Argonaute2 inhibits cell and tumor growth. Biochimica et biophysica acta 2013, 1830(3):2553-2561.
42. Tattikota SG, Rathjen T, McAnulty SJ, Wessels HH, Akerman I, van de Bunt M, Hausser J, Esguerra JL, Musahl A, Pandey AK et al: Argonaute2 mediates compensatory expansion of the pancreatic beta cell. Cell metabolism 2014, 19(1):122-134.
43. Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. Trends in molecular medicine 2014, 20(8):460-469.
44. Li Z, Rana TM: Therapeutic targeting of microRNAs: current status and future challenges. Nature reviews Drug discovery 2014, 13(8):622-638.
45. Meacham CE, Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501(7467):328-337.
46. Junttila MR, de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501(7467):346-354.
47. Horman SR, Janas MM, Litterst C, Wang B, MacRae IJ, Sever MJ, Morrissey DV, Graves P, Luo B, Umesalma S et al: Akt-mediated phosphorylation of argonaute 2 downregulates cleavage and upregulates translational repression of MicroRNA targets. Molecular cell 2013, 50(3):356-367.
48. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH et al: EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 2013, 497(7449):383-387.
49. Hauptmann J, Meister G: Argonaute regulation: two roads to the same destination. Developmental cell 2013, 25(6):553-554.
50. Myllyharju J: Prolyl 4-hydroxylases, master regulators of the hypoxia response. Acta Physiol (Oxf) 2013, 208(2):148-165.
51. Qi HH, Ongusaha PP, Myllyharju J, Cheng D, Pakkanen O, Shi Y, Lee SW, Peng J: Prolyl 4-hydroxylation regulates Argonaute 2 stability. Nature 2008, 455(7211):421-424.
52. MacFarlane LA, Gu Y, Casson AG, Murphy PR: Regulation of fibroblast growth factor-2 by an endogenous antisense RNA and by argonaute-2. Mol Endocrinol 2010, 24(4):800-812.
53. Laffont B, Corduan A, Ple H, Duchez AC, Cloutier N, Boilard E, Provost P: Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood 2013, 122(2):253-261.
54. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nature reviews Drug discovery 2007, 6(4):273-286.
55. Chen S, Xue Y, Wu X, Le C, Bhutkar A, Bell EL, Zhang F, Langer R, Sharp PA: Global microRNA depletion suppresses tumor angiogenesis. Genes & development 2014, 28(10):1054-1067.
56. Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, Ishida T, Dewa T, Kiwada H, Nango M et al: Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. Biochemical and biophysical research communications 2008, 368(2):243-248.
57. Kim BS, Im YB, Jung SJ, Park CH, Kang SK: Argonaute2 regulation for K+ channel-mediated human adipose tissue-derived stromal cells self-renewal and survival in nucleus. Stem cells and development 2012, 21(10):1736-1748.
58. Iosue I, Quaranta R, Masciarelli S, Fontemaggi G, Batassa EM, Bertolami C, Ottone T, Divona M, Salvatori B, Padula F et al: Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells. Cell death & disease 2013, 4:e926.
59. Neppl RL, Kataoka M, Wang DZ: Crystallin-alphaB regulates skeletal muscle homeostasis via modulation of argonaute2 activity. The Journal of biological chemistry 2014, 289(24):17240-17248.
60. Lv Z, Wei Y, Wang D, Zhang CY, Zen K, Li L: Argonaute 2 in cell-secreted microvesicles guides the function of secreted miRNAs in recipient cells. PloS one 2014, 9(7):e103599.
61. Hale A, Lee C, Annis S, Min PK, Pande R, Creager MA, Julian CG, Moore LG, Mitsialis SA, Hwang SJ et al: An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochimica et biophysica acta 2014, 1843(11):2528-2542.